• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

成功使用阿替利珠单抗联合化疗治疗肺高级别胎儿腺癌患者：一例报告。

Successful treatment with atezolizumab combination chemotherapy in a patient with high-grade fetal adenocarcinoma of the lung: A case report.

机构信息

Department of Respiratory Medicine, Kishiwada City Hospital, Kishiwada, Japan.

Department of Medical Oncology, Kishiwada City Hospital, Kishiwada, Japan.

出版信息

Thorac Cancer. 2023 Jan;14(2):214-217. doi: 10.1111/1759-7714.14768. Epub 2022 Dec 9.

DOI:10.1111/1759-7714.14768
PMID:36495048
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9834689/
Abstract

High-grade fetal lung adenocarcinoma (H-FLAC) is a rare tumor, with little known of its response to chemotherapy with or without an immune checkpoint inhibitor or of its molecular profile. We report the first case of a 56-year-old man with stage IV H-FLAC who was successfully treated with carboplatin plus nab-paclitaxel in combination with atezolizumab. In addition, the tumor was found to be positive for amplification of the human epidermal growth factor receptor 2 gene.

摘要

高级别胎儿肺腺癌（H-FLAC）是一种罕见的肿瘤，其对化疗联合或不联合免疫检查点抑制剂的反应以及分子谱特征知之甚少。我们报告了首例 56 岁男性 IV 期 H-FLAC 患者，他成功接受了卡铂加白蛋白紫杉醇联合阿替利珠单抗治疗。此外，该肿瘤被发现人表皮生长因子受体 2 基因扩增阳性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ff/9834689/1fa585815354/TCA-14-214-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ff/9834689/722af2457fe8/TCA-14-214-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ff/9834689/1fa585815354/TCA-14-214-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ff/9834689/722af2457fe8/TCA-14-214-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ff/9834689/1fa585815354/TCA-14-214-g003.jpg

相似文献

1
Successful treatment with atezolizumab combination chemotherapy in a patient with high-grade fetal adenocarcinoma of the lung: A case report.成功使用阿替利珠单抗联合化疗治疗肺高级别胎儿腺癌患者：一例报告。
Thorac Cancer. 2023 Jan;14(2):214-217. doi: 10.1111/1759-7714.14768. Epub 2022 Dec 9.
2
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.阿替利珠单抗联合卡铂加白蛋白紫杉醇化疗与单纯化疗一线治疗转移性非鳞状非小细胞肺癌（IMpower130）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
3
Combined Atezolizumab and Chemotherapy for a Patient With Double Primary Cancers.阿替利珠单抗联合化疗治疗双原发癌患者
In Vivo. 2020 Jan-Feb;34(1):389-392. doi: 10.21873/invivo.11785.
4
Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.阿替利珠单抗、贝伐珠单抗、卡铂和紫杉醇联合治疗同步原发性肺腺癌和肝细胞癌取得成功。
Intern Med. 2021 Oct 15;60(20):3273-3277. doi: 10.2169/internalmedicine.6442-20. Epub 2021 Apr 12.
5
Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.APPLE（WJOG11218L）研究的治疗原理和设计：阿特珠单抗联合铂类/培美曲塞加或不加贝伐珠单抗治疗晚期非鳞状非小细胞肺癌的多中心、开放标签、随机 3 期研究。
Clin Lung Cancer. 2020 Sep;21(5):472-476. doi: 10.1016/j.cllc.2020.03.010. Epub 2020 Apr 10.
6
Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.阿替利珠单抗联合化疗治疗晚期非小细胞肺癌的成本效果分析。
Int J Clin Pharm. 2020 Aug;42(4):1175-1183. doi: 10.1007/s11096-020-01076-3. Epub 2020 Jun 11.
7
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.可切除非小细胞肺癌患者新辅助阿替利珠单抗和化疗：一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7.
8
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.晚期非小细胞肺癌患者接受阿特珠单抗联合铂类双药化疗的长期生存随访。
Eur J Cancer. 2018 Sep;101:114-122. doi: 10.1016/j.ejca.2018.06.033. Epub 2018 Jul 24.
9
Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.阿特珠单抗联合治疗方案用于美国转移性非鳞状非小细胞肺癌一线治疗的成本效果分析。
JAMA Netw Open. 2019 Sep 4;2(9):e1911952. doi: 10.1001/jamanetworkopen.2019.11952.
10
First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: A case report and review of the literature.一线培美曲塞、卡铂联合安罗替尼治疗表皮生长因子受体野生型和间变性淋巴瘤激酶阴性且伴有脑转移的肺腺癌：一例报告并文献复习
Medicine (Baltimore). 2020 Sep 4;99(36):e22128. doi: 10.1097/MD.0000000000022128.

引用本文的文献

1
High-grade fetal adenocarcinoma of the lung misdiagnosed as male breast carcinoma: a case report and literature review.误诊为男性乳腺癌的高级别胎儿型肺腺癌：一例报告及文献复习
Front Oncol. 2023 Dec 6;13:1293534. doi: 10.3389/fonc.2023.1293534. eCollection 2023.

本文引用的文献

1
Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable -Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review.抗程序性死亡蛋白1（PD-1）疗法在不可切除的阳性肝样肺腺癌多线化疗后实现疾病控制：一例报告及文献综述
Onco Targets Ther. 2020 May 19;13:4359-4364. doi: 10.2147/OTT.S248226. eCollection 2020.
2
Comprehensive review of fetal adenocarcinoma of the lung.胎儿肺腺癌的综合综述。
Lung Cancer (Auckl). 2018 Aug 23;9:57-63. doi: 10.2147/LCTT.S137410. eCollection 2018.
3
A Mismatch Repair-Deficient Hepatoid Adenocarcinoma of the Lung Responding to Anti-PD-L1 Durvalumab Therapy Despite no PD-L1 Expression.
一例错配修复缺陷型肺肝样腺癌，尽管无程序性死亡配体1（PD-L1）表达，但对抗PD-L1药物度伐利尤单抗治疗有反应。
J Thorac Oncol. 2018 Jul;13(7):e120-e122. doi: 10.1016/j.jtho.2018.03.004.
4
HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types.在肝样腺癌和具有肠上皮分化的胃癌中经常过表达 HER2：35 例与 334 例其他组织学类型胃癌的比较。
J Clin Pathol. 2018 Jul;71(7):600-607. doi: 10.1136/jclinpath-2017-204928. Epub 2018 Jan 5.
5
Differences between low and high grade fetal adenocarcinoma of the lung: a clinicopathological and molecular study.肺低级别与高级别胎儿型腺癌的差异：一项临床病理及分子研究
J Thorac Dis. 2017 Jul;9(7):2071-2078. doi: 10.21037/jtd.2017.07.14.
6
High-grade fetal adenocarcinoma of the lung is a tumour with a fetal phenotype that shows diverse differentiation, including high-grade neuroendocrine carcinoma: a clinicopathological, immunohistochemical and mutational study of 20 cases.高级别胎儿型肺腺癌是一种具有胎儿表型的肿瘤，表现出多种分化，包括高级别神经内分泌癌：20例临床病理、免疫组化及突变研究
Histopathology. 2015 Dec;67(6):806-16. doi: 10.1111/his.12711. Epub 2015 Jun 5.
7
High-grade lung adenocarcinoma with fetal lung-like morphology: clinicopathologic, immunohistochemical, and molecular analyses of 17 cases.高分化肺腺癌伴胎儿肺样形态学特征：17 例的临床病理、免疫组化和分子分析。
Am J Surg Pathol. 2013 Jun;37(6):924-32. doi: 10.1097/PAS.0b013e31827e1e83.
8
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).实体瘤新的疗效评价标准：修订的RECIST指南（第1.1版）
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.